Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 at ASH 2012

Published: Tuesday, December 11, 2012
Last Updated: Tuesday, December 11, 2012
Bookmark and Share
68% transfusion independence response rate and 37% durable spleen response rate.

YM BioSciences Inc. has reported updated results from the 166 patient Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.

The results were presented this afternoon in an oral session at the 54th Annual Meeting of the American Society of Hematology underway in Atlanta, Georgia.

• 68% durable 12-week transfusion independence response rate with a maximal duration of response approaching three years and ongoing.
• The percentage of patients requiring transfusions decreased substantially, from 44% at baseline to below 10% at week 40 of treatment.
• 37% durable spleen response per IWG-MRT with a maximal duration of response of nearly 2.5 years and ongoing.
• The majority of subjects achieved a complete resolution or marked improvement of common constitutional symptoms.
• The majority of adverse events were Grade 1.

"These data continue to demonstrate that treatment with CYT387 results in significant, durable responses in transfusion dependency, splenomegaly and constitutional symptoms," said Dr. Nick Glover, President and CEO of YM BioSciences.

Dr. Glover continued, "The benefits CYT387 produces are highly encouraging for patients with myelofibrosis and underscore the clinical potential of this drug."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013
Company prepared for pivotal trials with CYT387 during the quarter.
Monday, November 12, 2012
YM BioSciences Reports CYT387 Phase I/II Results Selected by ASH Program Committee
Phase I/II results selected for oral presentation at ASH2012 conference.
Friday, October 12, 2012
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
Pivotal trials for CYT387 in myelofibrosis to begin in the second half of calendar 2012.
Tuesday, May 15, 2012
YM BioSciences Reports Operational and Financial Results
Company reports operational and financial results for the second quarter of fiscal 2012.
Friday, February 10, 2012
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011
Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported.
Tuesday, December 13, 2011
YM BioSciences Nimotuzumab Results Reported at SIOP Conference
Phase II study of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma.
Tuesday, November 01, 2011
YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results
Enrollment of phase I/II trial for CYT387 complete.
Monday, September 26, 2011
YM BioSciences Reports Interim Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASCO
Favorable safety and durable efficacy responses recorded.
Thursday, September 01, 2011
YM BioSciences Reports Updated 12-Week Phase I/II Results for its JAK1/JAK2 Inhibitor CYT387
Poster with broader update of trial results to be presented at ASCO.
Thursday, May 19, 2011
YM BioSciences Reports Fiscal Third Quarter 2011 Operational and Financial Results
Operational and financial results for the third quarter of fiscal 2011, ended March 31, 2011.
Thursday, May 12, 2011
YM BioSciences Reports Positive Updated Anemia Response Data for its JAK1/JAK2 Inhibitor CYT387
Results disclosed at First Annual Florence Meeting on Myeloproliferative Neoplasms in Florence, Italy.
Tuesday, April 19, 2011
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial
YM BioSciences Inc., a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, have announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.
Friday, January 21, 2011
YM BioSciences Reports Positive Interim Data from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Results including substantial Anemia response presented at the 52nd American Society of Hematology Annual meeting.
Tuesday, December 07, 2010
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
The Phase I/II clinical trial in patients with myelofibrosis has been expanded to five sites.
Friday, November 19, 2010
YM BioSciences to Present Poster on CYT387 at the European School of Haematology International Conference
CYT387 possesses an excellent enzymatic potency and selectivity profile which may provide significant clinical advantages.
Monday, October 04, 2010
Scientific News
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Common Drug Presents Fracture Risk To Older Women
Researchers are urging caution in prescribing one of the world’s most commonly issued drug groups, citing links to increased fracture risks in older Australian women.
Combining Epigenetic Therapies and Immunotherapies Improves Cancer Outcomes
Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs.
LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
Clinical study provides evidence for functional liver recovery after weight loss.
Landmark NIH Study Shows Intensive Blood Pressure Management May Save Lives
Lower blood pressure target greatly reduces cardiovascular complications and deaths in older adults.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos